US FDA Approves Bristol Mayers Squibb Cardio Drug ‘Camzyos’

The Food and Drug Administration (FDA) of the United States has given the approval to Camzyos of Bristol Myers Squibb for the purpose of treating the symptomatic obsutructive hypertrophic cardiomyopathy (obstructive HCM). The drug, which is formerly known as mavacamten, has been representing a potential and important addition to the cardiovascular stable, which is needing the fresh blood ahead of the decrease off the patent cliff later in the decade.

The drug ‘Camzyos’ had been at the centre of the company’s 13.1 billion dollars acquisition of MyoKardia back in the year 2020, and the HCM drug has been one of the four new launches that, the figures of the company can possibly reach at the top of the sales of over 4 billion dollars alone.

The company is largely depending on the Camzyos and several other medicines for the purpose of helping the preventing the decrease. Traditionally, treatment of HCM has been revolved around the mitigating symptoms along with the drugs such as beta-blockers. Samit Hirawat, chief medical officer at Bristol Myers said, the drug has been inhibiting cardiac myosin for the purpose of triggering the functional and symptomatic improvements.

He also said that, for the patients with the hypertrophic cardiomyopathy, the muscle fibers in the heart has been increasing in the number and also thickening, which has been responsible for causing the walls and septum, which has been separating the right and left heart to thicken.